Latest News Archive
Please select Category, Year, and then Month to display items
27 December 2019
|
Story Dr Cindé Greyling
|
Photo Supplied
KovsieInnovation at the UFS is bridging the gap between industry and academics with a powerful force. For too long, research remained an academic pursuit, with many innovative ideas stuck between the pages of a thesis – only to come alive during exclusive, short-lived conference proceeds.
KovsieInnovation
Recently, Gerard Verhoef, Director in the Directorate: Research Development (DRD), and his team from KovsieInnovation finalised their Innovation and Commercialisation Strategy in order to create a structured pathway for good ideas. The primary objective of KovsieInnovation – the UFS Innovation and Entrepreneurship Office – is to achieve sustainable growth in third-stream income from innovative research activities stemming from the UFS. “Potential successful ideas must be feasible, viable, and sustainable, and we formulated an eight-step plan to facilitate this,” Verhoef explains. Ultimately, the DRD wants to attract new and continuous research as a renowned academic knowledge partner that can foster, drive, and successfully commercialise innovative research activities; and in doing so, foster an entrepreneurial culture at the UFS.
Liquid Culture
One such success story is the development of Liquid Culture into a business of choice, supplying liquid yeast to breweries and bakeries. Christopher Rothmann and Dr Errol Cason are the driving forces behind this company that produces their sought-after and stable yeast product in the Department of Microbiology, Biochemistry and Food Biotechnology at the UFS. With world-class equipment and laboratories, they house one of the largest yeast-culture collections in the world.
Both Rothman and Dr Cason were home brewers for many years before starting to produce commercial batches. They believe it would not have been possible without the help of KovsieInnovation. This project was also one of the finalists in the National Entrepreneurship Intervarsity.
Christo Strydom Nutrition (CSN)
Another innovative way in which the UFS generates third-stream income via the DRD, is by partnering with already successful commercial products. One such example is the recent successful royalty agreement with CSN. With this transaction, the university unlocked its brand potential to the benefit of both the industry partner and the UFS. Quality assurance remains the key success factor for deals like this.
Haemophilia home infusion workshop
2017-12-17
Parents receive training for homecare of their children with haemophilia.
Photo Supplied
Caregivers for haemophilia patients, and patients themselves from around the Free State and Northern Cape attended a home infusion workshop held by the Clinical Skills unit in the Faculty of Health Sciences in July 2017. “It felt liberating and I feel confident to give the factor to my son correctly,” said Amanda Chaba-Okeke, the mother of a young patient, at the workshop. Her son, also at the workshop, agreed. “It felt lovely and good to learn how to administer factor VIII.”
Clinical skills to empower parents and communities
There were two concurrent sessions: one attended by doctors from the Haemophilia Treatment Centre, and the other attended by community members including factor VIII and XI recipients, caregivers and parents. The doctors’ meeting was shown informative videos and demonstrations on how to administer the newly devised factor VII and XI kit, and discussed the pressing need for trained nurses at local clinics. Dr Jaco Joubert, a haematologist, made an educational presentation to the community members.
The South African Haemophilia Foundation was represented by Mahlomola Sewolane, who gave a brief talk about the role of the organisation in relation to the condition. Meanwhile, procedural training in the simulation laboratory involved doctors and nurses helping participants to learn the procedures by using mannequins and even some volunteers from among the patients.
A medical condition causing serious complications
Haemophilia is a medical condition in which the ability of the blood to clot is severely impaired, even from a slight injury. The condition is typically caused by a hereditary lack of a coagulation factor, most often factor VIII. Usually patients must go through replacement therapy in which concentrates of clotting factor VIII (for haemophilia A) or clotting factor IX (for haemophilia B) are slowly dripped or injected into the vein, to help replace the clotting factor that is missing or low. Patients have to receive this treatment in hospital.